These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35039195)

  • 41. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
    Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
    Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.
    Misegades LK; Winter K; Harriman K; Talarico J; Messonnier NE; Clark TA; Martin SW
    JAMA; 2012 Nov; 308(20):2126-32. PubMed ID: 23188029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pertussis vaccine effectiveness following country-wide implementation of a hexavalent acellular pertussis immunization schedule in infants and children in Panama.
    Calvo AE; Tristán Urrutia AG; Vargas-Zambrano JC; López Castillo H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2389577. PubMed ID: 39164002
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic considerations for pertussis booster vaccination in adolescents.
    Hay JW; Ward JI
    Pediatr Infect Dis J; 2005 Jun; 24(6 Suppl):S127-33. PubMed ID: 15931140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pertussis vaccination in pregnancy in Canada: a cost-utility analysis.
    Abu-Raya B; Coyle D; Bettinger JA; Vaudry W; Halperin SA; Sadarangani M;
    CMAJ Open; 2020; 8(4):E651-E658. PubMed ID: 33077536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States.
    Kamiya H; Cho BH; Messonnier ML; Clark TA; Liang JL
    Vaccine; 2016 Apr; 34(15):1832-8. PubMed ID: 26899377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duration of pertussis immunity after DTaP immunization: a meta-analysis.
    McGirr A; Fisman DN
    Pediatrics; 2015 Feb; 135(2):331-43. PubMed ID: 25560446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.
    Scheifele DW; Ochnio JJ; Halperin SA
    Pediatr Infect Dis J; 2009 Nov; 28(11):985-9. PubMed ID: 19755930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands.
    de Greeff SC; Mooi FR; Schellekens JF; de Melker HE
    Pediatr Infect Dis J; 2008 Mar; 27(3):218-23. PubMed ID: 18277916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pertussis immunization of adolescents in the United States: an economic evaluation.
    Caro JJ; Getsios D; El-Hadi W; Payne K; O'Brien JA
    Pediatr Infect Dis J; 2005 May; 24(5 Suppl):S75-82. PubMed ID: 15876932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule.
    Stevenson M; Beard S; Finn A; Brennan A
    Vaccine; 2002 Mar; 20(13-14):1778-86. PubMed ID: 11906765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis.
    Kandeil W; van den Ende C; Bunge EM; Jenkins VA; Ceregido MA; Guignard A
    Expert Rev Vaccines; 2020 Jul; 19(7):621-638. PubMed ID: 32772755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.
    Casey JR; Pichichero ME
    Drugs; 2005; 65(10):1367-89. PubMed ID: 15977969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.